ATOM BIOSCIENCE & PHARMACEUTICAL
Atom Bioscience is a clinical-stage biotechnology company developing new treatments for inflammatory and metabolic diseases such as chronic gout and non-alcoholic steatohepatitis.
ATOM BIOSCIENCE & PHARMACEUTICAL
Industry:
Biotechnology Health Care
Founded:
2012-01-01
Address:
Suzhou, Jiangsu, China
Country:
China
Website Url:
http://www.atombp.com
Total Employee:
11+
Status:
Active
Total Funding:
160.15 M USD
Technology used in webpage:
Chinese Server Location
Similar Organizations
Allogene Therapeutics
Allogene Therapeutics is a biotechnology company catalyzing cancer treatment through the development of CAR T therapy.
Graphene Composites
Graphene Composites is a nano-technology startup that combines graphene with aerogel .
ImmunOs Therapeutics
ImmunOs Therapeutics is a clinical-stage biotechnology company.
KBP Biosciences
A multinational clinical stage biotechnology company.
Lion TCR
Lion TCR is a clinical-stage biotechnology company.
Lyten
Lyten is an advanced materials company that developed Lyten 3D Graphene™
Nuevocor
Nuevocor operates as a preclinical-stage biotech company.
OliX Pharmaceuticals
OliX is a clinical stage biotechnology company.
Panacea Biotec
Panacea Biotec is an Innovation driven Biotechnology company.
Themis Bioscience
Themis Bioscience is a start-up biotechnology company.
Current Employees Featured
Marc Gurwith Chief Medical Officer @ Atom Bioscience & Pharmaceutical
Chief Medical Officer
William (Dongfang) Shi CEO, President, Chairman, & Founder @ Atom Bioscience & Pharmaceutical
CEO, President, Chairman, & Founder
Founder
Investors List
Kaitai Capital
Kaitai Capital investment in Series D - Atom Bioscience & Pharmaceutical
Unifortune
Unifortune investment in Series D - Atom Bioscience & Pharmaceutical
NNFE Fund Management
NNFE Fund Management investment in Series D - Atom Bioscience & Pharmaceutical
HuaJin Securities
HuaJin Securities investment in Series D - Atom Bioscience & Pharmaceutical
Fortune Capital
Fortune Capital investment in Series D - Atom Bioscience & Pharmaceutical
ShenZhen GTJA Investment Group
ShenZhen GTJA Investment Group investment in Series C - Atom Bioscience & Pharmaceutical
Sequoia Capital China
Sequoia Capital China investment in Series C - Atom Bioscience & Pharmaceutical
Kaitai Capital
Kaitai Capital investment in Series C - Atom Bioscience & Pharmaceutical
Kingray Capital
Kingray Capital investment in Series C - Atom Bioscience & Pharmaceutical
Livzon Pharmaceutical Group
Livzon Pharmaceutical Group investment in Series C - Atom Bioscience & Pharmaceutical
Official Site Inspections
http://www.atombp.com Semrush global rank: 12.98 M Semrush visits lastest month: 78
- Host name: 43.143.100.25
- IP address: 43.143.100.25
- Location: Japan
- Latitude: 35.69
- Longitude: 139.69
- Timezone: Asia/Tokyo

More informations about "Atom Bioscience & Pharmaceutical"
Atom Bioscience & Pharmaceutical - Crunchbase
Headquarters Regions Asia-Pacific (APAC); Founded Date 2012; Founders William (Dongfang) Shi; Operating Status Active; Last Funding Type Series D; Also Known As Atom Bioscience, …See details»
Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.
Nov 1, 2024 JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new …See details»
Atom Therapeutics and China Medical System Holdings Enter …
Dec 3, 2024 Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from …See details»
About Atom - Atom Bioscience
Atom Therapeutics is a research-based pharmaceutical company engaged in new drug discovery and development on treatments for inflammatory and metabolic diseases. Among our drugs …See details»
News & Events - Atom Bioscience
Jan 2, 2024 News from Atom Therapeutics 21 May, 2024 Atom Bioscience Marks Gout Awareness Day with Video Detailing Risks of Hyperuricemia, the Cause of Gout PRESS …See details»
Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd.
Feb 6, 2023 The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. Jiangsu Atom …See details»
Atom Bioscience Names Hu Xianjun Clinical VP in China
Apr 21, 2024 PRESS RELEASE Atom Bioscience Names Hu Xianjun Clinical VP in China JIANGSU, China (April 18, 2024) – Atom Bioscience (Jiangsu Atom Bioscience and …See details»
Atom Bioscience and Pharmaceutical - Overview, News ... - ZoomInfo
View Atom Bioscience and Pharmaceutical (www.atombp.com) location in Jiangsu, China , revenue, industry and description. Find related and similar companies as well as employees …See details»
Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd.
了解Jiangsu Atom Bioscience & Pharmaceutical Co., Ltd. (江苏新元素医药科技有限公司)公司的药物管线,治疗领域,技术平台,以及它的10项临床试验, 48篇新闻,疾病领域:内分泌与代谢疾 …See details»
Atom Bioscience and Pharmaceutical - Datanyze
John@atombp.com: 7: last: Smith@atombp.com: Your Questions, Our Answers Get Free Access to Atom Bioscience and Pharmaceutical Contacts Info. What is Atom Bioscience and …See details»
Atom Bioscience获得8300万美元D轮融资,用于支持慢性痛风新疗 …
Oct 16, 2023 JIANGSU, China--(BUSINESS WIRE)--Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing best-in …See details»
Atom Therapeutics and China Medical System Holdings Enter
Dec 3, 2024 Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from …See details»
Atom Bioscience Raises $45 Million in Series C Round of
Jan 5, 2022 JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience (Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.), a clinical stage biotechnology company developing new …See details»
Atom Therapeutics and China Medical System Holdings Enter …
Dec 3, 2024 Atom Therapeutics Co. Ltd (Atom Therapeutics), a clinical stage biotechnology company developing best-in-class treatments for inflammatory and metabolic diseases, …See details»
Atom Bioscience Receives FDA IND Clearance for Clinical Trial of …
Jan 2, 2024 The company’s lead product, ABP-671, is in Phase 2b/3 clinical development for treatment of chronic gout . Another small molecule ABP-745 has shown significant efficacy …See details»
ABP-745 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 ABP-745 is an oral small molecule drug that also has potential applications for other anti-inflammatory diseases JIANGSU, China--(BUSINESS WIRE)-- Atom Bioscience …See details»
Atom Bioscience Raises $47 Million in Series C Round of Financing …
Jan 5, 2022 Atom Bioscience Raises $47 Million in Series C Round of Financing to Advance Development of Small Molecule Drugs for Inflammatory and Metabolic Diseases Funding will …See details»
Atom Therapeutics Receives FDA IND Clearance for ... - Atom …
Jan 19, 2024 The company’s lead product, ABP-671, is in Phase 2b/3 clinical development for treatment of chronic gout . Another small molecule ABP-745 has shown significant efficacy …See details»
Lingdolinurad - Drug Targets, Indications, Patents - Synapse
Jan 4, 2025 Atom Therapeutics and CMS will execute a Contract Sales Organization (CSO) business model. Under the agreement, Atom Therapeutics will receive a substantial sum from …See details»
Atom Bioscience Changes Name to Atom Therapeutics To Better …
Nov 12, 2024 PRESS RELEASE Atom Bioscience Changes Name to Atom Therapeutics To Better Reflect Focus on Development of Best-in-Class Novel Oral Drugs for Inflammatory and …See details»